- Home
- PRQR vs UNCY Comparison
PRQR vs UNCY Comparison
Compare PRQR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | UNCY |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.3M | 141.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PRQR | UNCY |
|---|---|---|
| Price | $1.45 | $6.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $7.67 | ★ $44.50 |
| AVG Volume (30 Days) | 408.8K | ★ 662.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $3.71 |
| 52 Week High | $3.10 | $11.00 |
Technical Indicators
Market Signals| Indicator | PRQR | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 48.17 |
| Support Level | $1.33 | $5.98 |
| Resistance Level | $1.54 | $6.78 |
| Average True Range (ATR) | 0.09 | 0.46 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 31.94 | 29.71 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.